Dr Sue Hartup

Nurse Research Fellow in Oncology

s.hartup@nhs.net / s.m.hartup@leeds.ac.uk


Registered General Nurse (1992), BSc (Hons) Biosciences and Health (2002), PGC Independent Practice in Health (2008), PGC Health Research (2014), Nurse Independent and Supplementary prescriber (2021), PhD (Jan 2022)


Sue was a Senior Breast Cancer Research Nurse who is currently working as a Nurse Research Fellow at the Leeds Cancer Centre, UK. Sue was awarded an NIHR Clinical Doctoral Research Fellowship in 2016 to undertake her PhD which she completed part time whilst continuing to work as senior breast research nurse.

She has particular interests in the identification of patient unmet needs and the coproduction of clinical trials to improve patient experience and outcomes. She is a staunch supporter of non-medical clinical academics, developing this role at Leeds with the support of the PCOR group and the Leeds Teaching Hospitals NHS Trust R&I department. This role is supported by the Leeds Hospitals Charity who have agreed to fund this development post until 2024. As a clinical academic nurse research fellow, she is working on a number of trials including international studies of PRO development, CTIMPs and QoL studies and is currently the co-developer and trial manager of the MARECA national study of breast cancer local recurrences. Sue provides expertise and support to other trials as a member of several trial management groups and steering committees and co-applicant on several successful grant applications. She also works alongside patients and supporters as an active West Yorkshire and Harrogate Cancer Alliance CancerSMART Champion. Sue is a member of the Academic and Research committee, a nursing committee member of the Association of Breast Surgeons, and an honorary lecturer at the University of Leeds. She also acts as a reviewer for the HTA and NIHR, European Journal of Cancer and Breast Cancer Now.

Sue is a member of the NCRI breast cancer group, was recently appointed national Deputy Chair of an NCRI working group. and is an active member of the EORTC Quality of Life group. She has collaborated both nationally and internationally with experts in breast cancer services, research, PROs, and clinical trials.

Having helped others develop research projects and trials for many years, she was a co-applicant on a successful £2.5 million HTA grant in 2013 (the Mammo-50 trial) which encouraged her to start designing her own research projects. She was awarded an HEE/NIHR ICA Programme Clinical Doctoral Research Fellowship for her PhD: The development and feasibility testing of a web-based intervention to support pain and symptom self-management in breast cancer surgery. This included a local audit, scoping review, systematic review, qualitative study with patient focus groups and staff interviews, intervention development and a feasibility study to test the web-based intervention. Sue is also currently working on 3 locally developed studies; one exploring methods for increasing breast cancer patient adherence to endocrine therapy; one for measuring and monitoring pain in metastatic clinics and a weight management programme in breast cancer.

Research Interests

  • Breast cancer symptom self-management including using PROs to monitor symptoms and tailor support
  • Breast cancer radiotherapy clinical trials
  • Measurement of patient reported outcomes (PROs) and quality of life in routine clinical practice
  • Family history of breast cancer
  • Medication adherence to reduce recurrence
  • Imaging studies including breast density
  • Developing non-medical clinical academic roles and studies


Bundred N, Porta N, Murray Brunt AM, Cramer A, Hanby A, Shaaban AM, Rakha EA, Armstrong A, Cutress RI, Dodwell D, Emson MA, Evans A, Hartup SM, Horgan K, Miller SE, McIntosh SA, Morden JP, Naik J, Narayanan S, Ooi J, Skene AI, Cameron DA, Bliss JM. Combined Peri-operative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomised UK EPHOS-B Trial Long term result. Clinical Cancer Research. 2022.

Smith SG, Ellison R, Hall L, Clark J, Hartley S, Mason E, Metherell J, Olivier C, Napp V, Naik J, Buckley S, Hirst C, Hartup S, Neal RD, Velikova G, Farrin A, Collinson M, Graham CD. Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial. 2021

D.G. Evans, S. Thomas, J. Caunt, A. Burch, A.R. Brentnall, L. Roberts, A. Howell, M.Wilson, R. Fox, S. Hillier, D.M. Sibbering, S. Moss, M.G.Wallis, D.M. Eccles, FH02 study group , S. Duffy. Final Results of the Prospective FH02 Mammographic Surveillance Study Of Women Aged 35–39 at Increased Familial Risk of Breast Cancer. EClinicalMedicine 16/1/2019

Z. E. Winters, M. Afzal, C. Rutherford, B.Holzner, G. Rumpold, R. A. da Costa Vieira, S. Hartup, K. Flitcroft , V. Bjelic-Radisic, A.Oberguggenburger, M. Panouilleres, M. Mani, G. Catanuto, M.Douek, J. Kokan, P. Sinai and M.T.King on behalf of the European Organisation for Research and Treatment of Cancer Quality of Life Group∗ Internal validation of the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) for women undergoing breast reconstruction: the QLQBRECON23. British Journal of Surgery Feb 2018; 105(3): 209-222

Bundred, N; Cameron, D; Armstrong, Anne C; Brunt, A; Cramer, Angela; Dodwell, D; Evans, A; Hanby, A; Hartup, S; Hong, A; Horgan, K; Khattak, I; Morden, J; Naik, J; Narayan, S; Ooi, J; Shaaban, A; Smith, R; Webster-Smith, M; Bliss, J. Effects of perioperative lapatinib and trastuzumab, alone and in combination, in early HER2+breast cancer – the UK EPHOS-B trial (CRUK/08/002). European Journal of Cancer 2016

Hartup S et al. Persistent post-operative pain in breast cancer survivors. Psycho-oncology special edition Volume 25, Issue S3, October 2016 Pages 3–1952016

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016 Feb 27;387(10021):866-73

Strachan C, Dave R, Hartup S, Sharma N, Highes T, Horgan K. P095. Chemotherapy trends in early breast cancer in the under 55s in 2014. EJSO June 2015 Vol 41 iss 6, page S53

Dunn JA, Donnelly PK, Marshall A, Wilcox M, Watson E, Young A, Balmer C, Ramirez M, Hartup S, Maxwell AJ, Evans AJ; Mammo-50 trial management group. Follow-up in Early Breast Cancer – A Surgical and Radiological Perceptive. Clin Oncol (R Coll Radiol). 2014 Oct;26(10):625-9. doi: 10.1016/j.clon.2014.06.015. Epub 2014 Jul 16.

Winters ZE, Emson M, Griffin C, Mills J, Hopwood P, Bidad N, MacDonald L, Turton EPL, Horne R, Bliss JM, The QUEST trial management group. Learning from the QUEST multicentre feasibility randomization trials in breast reconstruction after mastectomy. BJS 2014 Dec: https://doi.org/10.1002/bjs.9690

Evans G, Barwell J, Eccles DM, Collins A, Izatt L, Jacobs C, Donaldson A, Brady AF, Cuthbert A, Harrison R, Thomas S, Howell A, The FH02 Study Group, RGC teams, Miedzybrodzka Z, and Murray A. The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Research 2014, 16:442

Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A; IBIS-II investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebocontrolled trial. Lancet. 2014 Mar 22;383(9922):1041-8. doi: 10.1016/S0140-6736(13)62292-8. Epub 2013 Dec 12. Erratum in: Lancet. 2014 Mar 22;383(9922):1040.